Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MAZE
STRONG SELLMaze Therapeutics, Inc. · Healthcare · United States · $1.5B · Avg Vol: $20M/d
COMPANY DESCRIPTION
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary "human genetic discovery engine" to identify and validate novel drug targets for common diseases. By integrating human genetics and functional genomics, the company aims to develop precision medicines that modulate disease-modifying genes. Its competitive advantage lies in its unique platform for identifying genetically-driven therapeutic opportunities and its focus on developing highly targeted treatments for underserved patient populations.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 167.5M | 0 | — | — | 20.0M | 8.8M | -62.5% |
| EPS | -3.29 | -2.87 | 0.08 | -3.05 | — | -2.37 | -2.67 | -3.19 | — |
| Shares | 43.8M | 43.8M | 43.8M | 49.3M | +12.7% | 55.3M | — | — | — |
| Debt | 32.1M | 49.6M | 26.6M | 23.3M | -10.1% | 61.2M | — | — | — |
| Equity | -282.5M | -373.8M | -311.2M | 355.0M | — | — | — | — | — |
| Op CF | -99.2M | -86.8M | 76.0M | -111.9M | — | -121.5M | — | — | — |
| Inv CF | -3.2M | -0.4M | -1.1M | -171.0M | — | — | — | — | — |
| Fin CF | 1.7M | 16.4M | 92.8M | 275.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MAZE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MAZE | Maze Therapeutics, Inc.(you) | $1.5B | 10 | STRONG SELL |
| AKTS | Aktis Oncology, Inc. | $1.3B | 10 | STRONG SELL |
| NTLA | Intellia Therapeutics, Inc. | $1.5B | 15 | STRONG SELL |
| GENB | Generate Biomedicines, Inc. | $1.7B | 8 | STRONG SELL |
| OCUL | Ocular Therapeutix, Inc. | $1.9B | 9 | STRONG SELL |
| INBX | Inhibrx Biosciences, Inc. | $1.2B | 10 | STRONG SELL |
| AVLN | Avalyn Pharma Inc. | $1.2B | 9 | STRONG SELL |
| RXRX | Recursion Pharmaceuticals, Inc. | $1.6B | 5 | STRONG SELL |
| KARD | Kardigan, Inc. | $1.9B | 8 | STRONG SELL |
| CRVS | Corvus Pharmaceuticals, Inc. | $1.1B | 11 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.5%